Reshmi Parameswaran

I (Reshmi Parameswaran) am a scientist working in the field of cancer immunotherapy for past 22 years. I received my Ph.D degree from Weizmann Institute of Israel in cell biology and then did postdoctoral training at Children's Hospital Los Angeles working on understanding the drug resistance mechanism of Acute Lymphoblastic Leukemia. Later I moved to Case Western University and my laboratory is focusing on developing new immunotherapies for liquid and solid cancers. We generated a new BAFF ligand based CAR-T therapy to treat B cell cancers and this entered into three clinical trials for treating lymphoma, multiple myeloma and autoimmune lupus. All are currently in phase-1 clinical trials. I have published about 25 articles on cancer immunotherapy and received multiple research grants to develop new immunotherapy strategies for cancer. I am committed to find the reason why HCLv patients fail chemotherapy and to develop a new therapy to sensitize these patients to standard chemotherapy.